Stay updated on Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial
Sign up to get notified when there's something new on the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page.

Latest updates to the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page
- Check3 days agoChange DetectedThe page’s footer software/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.”SummaryDifference0.0%

- Check10 days agoChange DetectedRevision: v3.5.2 supersedes v3.5.0 on the page.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedIgA glomerulonephritis was added as a listed condition, aligning with IgA nephropathy. This text update does not modify study design, eligibility criteria, or measured outcomes.SummaryDifference0.0%

- Check39 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedPage revision history updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no substantive study details appear to have changed, To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bardoxolone Methyl in Rare Kidney Diseases Clinical Trial page.